<DOC>
	<DOC>NCT01797809</DOC>
	<brief_summary>The objective of this PMS is to gain information about safety and efficacy in real practice as a regulatory commitment required by KFDA(Korea Food and drug administration)</brief_summary>
	<brief_title>Qlaira rPMS (Regulatory Post Marketing Surveillance) Study in Korea</brief_title>
	<detailed_description />
	<criteria>Signed and dated informed consent Women after menarche and before menopause Women requesting contraception or Women diagnosed by a physician as having HMB due to nonorganic cause who are also requesting contraception Women who are prescribed QlairaÂ® for the first time, during the study period All contraindications according to the local marketing authorization have to be considered.</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>